Subscribe
2019-11-21
21 November 2019Big PharmaRory O'Neill

LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit

English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at  Life Sciences Patent Network Europe today, November 21.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.

More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB